This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
3 MedTech Sectors Benefiting Despite COVID-19 Resurgence
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.
Omnicell (OMCL) Opens New Software Development Center in India
by Zacks Equity Research
Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip
by Urmimala Biswas
Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Omnicell (OMCL) Enhances Medication Management With New Release
by Zacks Equity Research
Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice
by Zacks Equity Research
Omnicell (OMCL) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic
by Zacks Equity Research
Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Omnicell (OMCL) possesses solid growth attributes, which could help it handily outperform the market.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.
Omnicell (OMCL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 21.25% and 2.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow
by Zacks Equity Research
Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.
CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?